Precigen (PGEN) Competitors $3.59 -0.20 (-5.28%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$3.62 +0.03 (+0.84%) As of 04:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PGEN vs. CRSP, PTCT, ACAD, MENS, PCVX, KRYS, ARWR, ACLX, ADMA, and MIRMShould you be buying Precigen stock or one of its competitors? The main competitors of Precigen include CRISPR Therapeutics (CRSP), PTC Therapeutics (PTCT), ACADIA Pharmaceuticals (ACAD), Jyong Biotech (MENS), Vaxcyte (PCVX), Krystal Biotech (KRYS), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), ADMA Biologics (ADMA), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. Precigen vs. Its Competitors CRISPR Therapeutics PTC Therapeutics ACADIA Pharmaceuticals Jyong Biotech Vaxcyte Krystal Biotech Arrowhead Pharmaceuticals Arcellx ADMA Biologics Mirum Pharmaceuticals CRISPR Therapeutics (NASDAQ:CRSP) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings. Do analysts recommend CRSP or PGEN? CRISPR Therapeutics presently has a consensus target price of $71.60, indicating a potential upside of 23.79%. Precigen has a consensus target price of $8.25, indicating a potential upside of 129.81%. Given Precigen's stronger consensus rating and higher probable upside, analysts clearly believe Precigen is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CRISPR Therapeutics 1 Sell rating(s) 7 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.47Precigen 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media favor CRSP or PGEN? In the previous week, CRISPR Therapeutics had 5 more articles in the media than Precigen. MarketBeat recorded 11 mentions for CRISPR Therapeutics and 6 mentions for Precigen. Precigen's average media sentiment score of 1.51 beat CRISPR Therapeutics' score of 0.94 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is CRSP or PGEN more profitable? CRISPR Therapeutics has a net margin of -1,229.43% compared to Precigen's net margin of -2,868.66%. CRISPR Therapeutics' return on equity of -20.05% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets CRISPR Therapeutics-1,229.43% -20.05% -17.09% Precigen -2,868.66%-842.83%-78.98% Which has better valuation & earnings, CRSP or PGEN? Precigen has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCRISPR Therapeutics$37.31M141.00-$366.25M-$5.43-10.65Precigen$3.92M272.89-$126.24M-$0.42-8.55 Which has more risk & volatility, CRSP or PGEN? CRISPR Therapeutics has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Do insiders and institutionals believe in CRSP or PGEN? 69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 47.1% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryPrecigen beats CRISPR Therapeutics on 8 of the 15 factors compared between the two stocks. Get Precigen News Delivered to You Automatically Sign up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PGEN vs. The Competition Export to ExcelMetricPrecigenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.13B$3.15B$5.80B$10.16BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-8.5521.2475.1126.39Price / Sales272.89431.67511.76177.24Price / CashN/A44.4425.8129.91Price / Book27.629.6413.456.28Net Income-$126.24M-$53.20M$3.29B$270.38M7 Day Performance-13.08%0.07%0.08%1.89%1 Month Performance22.11%4.27%4.59%6.01%1 Year Performance259.07%9.62%75.30%25.26% Precigen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PGENPrecigen4.5611 of 5 stars$3.59-5.3%$8.25+129.8%+241.9%$1.13B$3.92M-8.55190Positive NewsCRSPCRISPR Therapeutics3.2445 of 5 stars$54.10-1.4%$71.60+32.3%+18.2%$4.92B$37.31M-9.96460PTCTPTC Therapeutics3.8103 of 5 stars$56.95-0.5%$69.00+21.2%+73.5%$4.52B$806.78M8.171,410Insider TradeACADACADIA Pharmaceuticals4.2112 of 5 stars$25.39+0.5%$28.88+13.7%+51.2%$4.28B$957.80M19.09510MENSJyong BiotechN/A$55.68+6.4%N/AN/A$4.23BN/A0.0031PCVXVaxcyte2.347 of 5 stars$32.41-1.8%$130.00+301.1%-73.3%$4.21BN/A-7.89160Positive NewsKRYSKrystal Biotech4.9572 of 5 stars$145.20-3.4%$210.38+44.9%-22.8%$4.20B$290.52M29.51210Positive NewsAnalyst ForecastARWRArrowhead Pharmaceuticals4.1542 of 5 stars$27.17-6.6%$43.14+58.8%+33.4%$4.02B$572.98M-21.23400ACLXArcellx2.1231 of 5 stars$71.11-2.1%$114.31+60.7%-2.2%$3.94B$56.98M-20.7980Positive NewsADMAADMA Biologics3.6934 of 5 stars$16.42-2.7%$27.67+68.5%-15.4%$3.92B$426.45M19.09530Positive NewsMIRMMirum Pharmaceuticals3.3216 of 5 stars$77.39+1.7%$74.13-4.2%+80.4%$3.89B$336.89M-63.96140Positive News Related Companies and Tools Related Companies CRSP Competitors PTCT Competitors ACAD Competitors MENS Competitors PCVX Competitors KRYS Competitors ARWR Competitors ACLX Competitors ADMA Competitors MIRM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PGEN) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precigen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
